Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

VBI Vaccines, Inc. - Ordinary Shares (NQ: VBIV )

0.0653 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about VBI Vaccines, Inc. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in Upcoming Investor Conferences
From VBI Vaccines Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 11, 2022
Upgrades 
Via Benzinga
VBI Vaccines, Agenus Ink Partnership For Combination Brain Cancer Therapy
Via Benzinga
VBI Vaccines Announces Presentation of Data from Ongoing Phase 2a Study of VBI-1901 at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
From Agenus Inc.
Via GlobeNewswire
VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
From VBI Vaccines Inc.
Via Business Wire
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®
From VBI Vaccines Inc.
Via Business Wire
Why Chimerix Is Trading Higher By Over 19%, Here Are 53 Stocks Moving In Monday's Mid-Day Session
Gainers Advanced Human Imaging Limited (NASDAQ: AHI) shares jumped 53% to $1.04. Advanced Human Imaging announced Sunday it signed a Master Services Agreement with Estonia-based Activate Health OÜ. 
Via Benzinga
Why Hill International Is Trading Higher By 15%; Here Are 30 Stocks Moving Premarket
Gainers NewAge, Inc. (NASDAQ: NBEV) shares rose 19.7% to $0.2432 in pre-market trading. NewAge recently received Nasdaq notice on late filing of its form 10-Q. 
Via Benzinga
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday. 
Via Benzinga
Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66. 
Via Benzinga
Bed Bath & Beyond, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
  Bed Bath & Beyond Inc. (NASDAQ: BBBY) fell 23.3% to $17.71 following a Form 144 filing by RC Ventures, which suggested the firm proposed to sell 7.78 million common shares and certain call options.... 
Via Benzinga
VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update
From VBI Vaccines Inc.
Via Business Wire
Why Is Conagra Brands Dropping By More Than 8%? 43 Stocks Moving In Thursday's Mid-Day Session
Gainers Shineco, Inc. (NASDAQ: SISI) shares climbed 24.5% to $1.2201 on heavy volume. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, investors! We're starting off the day with a breakdown of the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
This Healthcare Stock is Down By More Than 50%: Here's 25 Stocks Moving Premarket
Gainers 
Via Benzinga
VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
From VBI Vaccines Inc.
Via Business Wire
The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
22 Stocks Moving in Thursday's Pre-Market Session
Gainers WISeKey International Holding AG (NASDAQ: WKEY) rose 74.4% to $2.32 in pre-market trading. WISeKey International recently issued 2022 first-half revenue guidance for its IoT segment. 
Via Benzinga
VBI Vaccines Announces Results of Annual General Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma
From VBI Vaccines Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 269 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 1214 companies set new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.